192 institutions hold shares in Agenus Inc. (AGEN), with 16.62M shares held by insiders accounting for 8.12% while institutional investors hold 57.07% of the company’s shares. The shares outstanding are 192.97M, and float is at 173.55M with Short Float at 13.85%. Institutions hold 52.44% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 14.52 million shares valued at $46.17 million. The investor’s holdings represent 7.09% of the AGEN Shares outstanding. As of Dec 30, 2020, the second largest holder is RTW Investments LP with 12.86 million shares valued at $40.91 million to account for 6.29% of the shares outstanding. The other top investors are Oracle Investment Management Inc which holds 11.85 million shares representing 5.79% and valued at over $37.69 million, while State Street Corporation holds 5.03% of the shares totaling 10.3 million with a market value of $32.76 million.
Agenus Inc. (NASDAQ: AGEN) is -4.40% lower on its value in year-to-date trading and has touched a low of $2.27 and a high of $5.95 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AGEN stock was last observed hovering at around $2.87 in the last trading session, with the day’s gains setting it 0.17% off its average median price target of $7.50 for the next 12 months. It is also 62.0% off the consensus price target high of $8.00 offered by 3 analysts, but current levels are 56.57% higher than the price target low of $7.00 for the same period.
Currently trading at $3.04, the stock is -0.41% and -18.98% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.79 million and changing 5.92% at the moment leaves the stock -20.30% off its SMA200. AGEN registered 28.27% gain for a year compared to 6-month loss of -24.94%. The firm has a 50-day simple moving average (SMA 50) of $3.4576 and a 200-day simple moving average (SMA200) of $3.7620.
The stock witnessed a -3.80% gain in the last 1 month and extending the period to 3 months gives it a -4.40%, and is 6.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.86% over the week and 7.54% over the month.
Agenus Inc. (AGEN) has around 359 employees, a market worth around $589.67M and $88.20M in sales. Distance from 52-week low is 33.92% and -48.91% from its 52-week high.
Agenus Inc. (AGEN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Agenus Inc. (AGEN) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.30, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Agenus Inc. is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.31 with sales reaching $14.54M over the same period.The EPS is expected to shrink by -31.40% this year, but quarterly earnings will post -13.30% year-over-year. Quarterly sales are estimated to shrink -3.90% in year-over-year returns.
Agenus Inc. (AGEN) Insider Activity
The most recent transaction is an insider sale by INCYTE CORP, the company’s 10% Owner. SEC filings show that INCYTE CORP sold 141,920 shares of the company’s common stock on Jun 17 at a price of $3.66 per share for a total of $0.52 million. Following the sale, the insider now owns 16.97 million shares.
Agenus Inc. disclosed in a document filed with the SEC on Jun 16 that INCYTE CORP (10% Owner) sold a total of 72,080 shares of the company’s common stock. The trade occurred on Jun 16 and was made at $3.66 per share for $0.26 million. Following the transaction, the insider now directly holds 17.11 million shares of the AGEN stock.
Still, SEC filings show that on Jun 15, INCYTE CORP (10% Owner) disposed off 384,025 shares at an average price of $3.57 for $1.37 million. The insider now directly holds 17,186,968 shares of Agenus Inc. (AGEN).
Agenus Inc. (AGEN): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 22.74% up over the past 12 months and Bristol-Myers Squibb Company (BMY) that is 14.40% higher over the same period. Short interest in the company’s stock has risen 0.96% from the last report on Feb 11, 2021 to stand at a total of 23.81 million short shares sold with a short interest ratio of 7.93.